Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HDAC-IN-31 is a selective, potent, orally active HDAC inhibitor that acts on HDAC1 (IC50: 84.90 nM), HDAC2 (IC50: 168.0 nM), HDAC3 (IC50: 442.7 nM), HDAC8 (IC50<10000 nM). HDAC-IN-31 has good anti-tumour effects. HDAC-IN-31 has shown potential research value in diffuse large B-cell lymphoma.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | HDAC-IN-31 is a selective, potent, orally active HDAC inhibitor that acts on HDAC1 (IC50: 84.90 nM), HDAC2 (IC50: 168.0 nM), HDAC3 (IC50: 442.7 nM), HDAC8 (IC50>10000 nM). HDAC-IN-31 has good anti-tumour effects. HDAC-IN-31 has shown potential research value in diffuse large B-cell lymphoma. |
Molecular Weight | 412.48 |
Formula | C25H24N4O2 |
CAS No. | 1916505-13-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
HDAC-IN-31 1916505-13-9 inhibitor inhibit